# Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

> **NCT04113187** · PHASE3 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 15 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Osler Weber Rendu Disease

## Interventions

- **DRUG:** Propranolol treatment
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04113187
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113187, "Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04113187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*